Lumiradx lab analysis confirms its covid-19 antigen test detects the omicron variant

London, jan. 14, 2022 /prnewswire/ -- lumiradx (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of covid-19 variants show its sars-cov-2 antigen test detects the omicron variant.  in-house wet testing with live omicron virus demonstrated that the lumiradx sars-cov-2 antigen test detects the omicron variant with comparable sensitivity to other variants.
LMDX Ratings Summary
LMDX Quant Ranking